Kazumoto Murata

Prof. Kazumoto Murata

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2019 in Hepatology
Verified
Journal Article
Closed access
PDF file
KMKazumoto Murata
Kazumoto Murata
STSenko Tsukuda
Senko Tsukuda
FSFutoshi Suizu
Futoshi Suizu
AKAkihiro Kimura
Akihiro Kimura
MSMasaya Sugiyama
Masaya Sugiyama
MMMasashi Mizokami
Masashi Mizokami

1 July 2021 in Virus Research
Verified
Journal Article
Closed access
TNTsutomu Nishizawa
Tsutomu Nishizawa
MTMasaharu Takahashi
Masaharu Takahashi
BTBira Tsatsralt-Od
Bira Tsatsralt-Od
KNKhurelbaatar Nyamdavaa
Khurelbaatar Nyamdavaa
NDNyamkhuu Dulmaa
Nyamkhuu Dulmaa
HOHiroaki Okamoto
Hiroaki Okamoto

23 March 2022 in Journal of Virology
Verified
Journal Article
Closed access
PPPutu Prathiwi Primadharsini
Putu Prathiwi Primadharsini
SNShigeo Nagashima
Shigeo Nagashima
TNTakashi Nishiyama
Takashi Nishiyama
MTMasaharu Takahashi
Masaharu Takahashi
KMKazumoto Murata
Kazumoto Murata
HOHiroaki Okamoto
Hiroaki Okamoto
Bioluminescent reporter viruses are essential tools in molecular virological research. They have been widely used to investigate viral life cycles and in the development of antiviral drugs.

28 September 2023 in Journal of Virology
Verified
Journal Article
Closed access
SNShigeo Nagashima
Shigeo Nagashima
PPPutu Prathiwi Primadharsini
Putu Prathiwi Primadharsini
TNTakashi Nishiyama
Takashi Nishiyama
MTMasaharu Takahashi
Masaharu Takahashi
KMKazumoto Murata
Kazumoto Murata
HOHiroaki Okamoto
Hiroaki Okamoto
Previously, we developed an infectious hepatitis E virus (HEV) harboring the nanoKAZ gene in the hypervariable region of the open reading frame 1 (ORF1) of the HEV3b (JE03-1760F/P10) genome and demonstrated the usefulness for screening anti-HEV drugs that inhibit the early infection process. In the present study, we constructed another reporter HEV (HEV3b-HiBiT) by placing a minimized HiBiT tag derived from NanoLuc luciferase at the 3′-end of the viral capsid (ORF2) coding sequence. It replicated efficiently in PLC/PRF/5 cells, produced membrane-associated particles identical to those of the parental virus, and was genetically stable and infectious. The HiBiT tag was fused to both secreted ORF2s (ORF2s-HiBiT) and ORF2c capsid protein (ORF2c-HiBiT). The ORF2c-HiBiT formed membrane-associated HEV particles (eHEV3b-HiBiT). By treating these particles with digitonin, we demonstrated that the HiBiT tag was expressed on the surface of capsid and was present inside the lipid membrane. To simplify the measurement of luciferase activity and provide a more convenient screening platform, we constructed an ORF2s-defective mutant (HEV3b-HiBiT/ΔORF2s) in which the secreted ORF2s are suppressed. We used this system to evaluate the effects of introducing small interfering RNAs and treatment with an inhibitor or accelerator of exosomal release on HEV egress and demonstrated that the effects on virus release can readily be analyzed. Therefore, HEV3b-HiBiT and HEV3b-HiBiT/ΔORF2s reporters may be useful for investigating the virus life cycle and can serve as a more convenient screening platform to search for candidate drugs targeting the late stage of HEV infection such as particle formation and release. IMPORTANCE: The construction of recombinant infectious viruses harboring a stable luminescence reporter gene is essential for investigations of the viral life cycle, such as viral replication and pathogenesis, and the development of novel antiviral drugs. However, it is difficult to maintain the stability of a large foreign gene inserted into the viral genome. In the present study, we successfully generated a recombinant HEV harboring the 11‐amino acid HiBiT tag in the ORF2 coding region and demonstrated the infectivity, efficient virus growth, particle morphology, and genetic stability, suggesting that this recombinant HEV is useful for in vitro assays. Furthermore, this system can serve as a more convenient screening platform for anti-HEV drugs. Thus, an infectious recombinant HEV is a powerful approach not only for elucidating the molecular mechanisms of the viral life cycle but also for the screening and development of novel antiviral agents.

1 January 2020 in Cytokine
Verified
Journal Article
Closed access
KMKazumoto Murata
Kazumoto Murata
JKJong-Hon Kang
Jong-Hon Kang
SNShigeo Nagashima
Shigeo Nagashima
TMTakeshi Matsui
Takeshi Matsui
YKYoshiyasu Karino
Yoshiyasu Karino
HOHiroaki Okamoto
Hiroaki Okamoto

20 March 2023 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
KMKazumoto Murata
Kazumoto Murata
MMMasashi Mizokami
Masashi Mizokami